IR@PKUHSC  > 北京大学临床肿瘤学院
学科主题临床医学
Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer
Wang, Zhi-jie1,2; An, Tong-tong1; Mok, Tony4; Yang, Lu1; Bai, Hua1,2; Zhao, Jun1,2; Duan, Jian-chun1,2; Wu, Mei-na1,2; Wang, Yu-yan1,2; Li, Ping-ping1,3; Sun, Hong3; Yang, Ping5; Wang, Jie1,2
关键词Egfr Tyrosine Kinase Inhibitor Maintenance Therapy Non-small-cell Lung Cancer
刊名CHINESE JOURNAL OF CANCER RESEARCH
2011-06-01
DOI10.1007/s11670-011-0112-5
23期:2页:112-117
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology
研究领域[WOS]Oncology
关键词[WOS]PHASE-III TRIAL ; FACTOR RECEPTOR MUTATIONS ; GEFITINIB ; GEMCITABINE ; ERLOTINIB ; BEVACIZUMAB ; CARBOPLATIN ; CISPLATIN ; PLACEBO ; TUMORS
英文摘要

To analyze the outcomes of patients who received TKI immediately after the first-line without progression as maintenance treatment (immediate group) vs. those received delayed treatment upon disease progression as second-line therapy (delayed group).

The study included 159 no-small-cell lung cancer (NSCLC) patients who received gefitinib or erlotinib as maintenance treatment in the immediate group (85 patients) or as second-line therapy in the delayed group (74 patients). The primary end point was progression-free survival (PFS). EGFR mutation status was detected using denaturing high-performance liquid chromatography (DHPLC).

PFS was 17.3 and 16.4 months in the immediate and delayed groups, respectively (hazard ratio [HR], 0.99; 95% Confidence Interval [CI]: 0.69-1.42; P=0.947). In a subgroup analysis that included only patients with EGFR mutation, however, PFS was significantly longer in the immediate group than in the delayed group (HR, 0.48; 95% CI: 0.27-0.85; P=0.012). In patients with wild type EGFR, the risk for disease progression was comparable between the two groups (HR, 1.23; 95% CI: 0.61-2.51; P=0.564). No significant difference was demonstrated between the immediate and delayed group in terms of the overall survival (OS) (26.1 months vs. 21.6 months, respectively; HR=0.53; 95% CI: 0.27 to 1.06; P=0.072). There was also no difference in the incidence of adverse events between the two groups.

EGFR TKI maintenance improves PFS in patients with EGFR mutation. Prospectively designed clinical studies that compare TKI immediate vs. delayed treatment after first-line chemotherapy upon disease progression are needed.

语种英语
WOS记录号WOS:000290804600005
项目编号81025012 ; 30772472
资助机构China National Funds for Distinguished Young Scientists ; Capital Development Foundation
引用统计
被引频次:2[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52025
专题北京大学临床肿瘤学院
北京大学临床肿瘤学院_胸部肿瘤内科
北京大学临床肿瘤学院_中西医结合科暨老年肿瘤科
作者单位1.Gen Hosp Navy, Dept Oncol, Beijing, Peoples R China
2.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100871, Peoples R China
3.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Thorac Med Oncol, Beijing 100871, Peoples R China
4.Peking Univ, Sch Oncol, Beijing Canc Hosp & Inst, Dept Integrat Med, Beijing 100871, Peoples R China
5.Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
推荐引用方式
GB/T 7714
Wang, Zhi-jie,An, Tong-tong,Mok, Tony,et al. Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer[J]. CHINESE JOURNAL OF CANCER RESEARCH,2011,23(2):112-117.
APA Wang, Zhi-jie.,An, Tong-tong.,Mok, Tony.,Yang, Lu.,Bai, Hua.,...&Wang, Jie.(2011).Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer.CHINESE JOURNAL OF CANCER RESEARCH,23(2),112-117.
MLA Wang, Zhi-jie,et al."Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer".CHINESE JOURNAL OF CANCER RESEARCH 23.2(2011):112-117.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Zhi-jie]的文章
[An, Tong-tong]的文章
[Mok, Tony]的文章
百度学术
百度学术中相似的文章
[Wang, Zhi-jie]的文章
[An, Tong-tong]的文章
[Mok, Tony]的文章
必应学术
必应学术中相似的文章
[Wang, Zhi-jie]的文章
[An, Tong-tong]的文章
[Mok, Tony]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。